4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus PT from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $47.14.

Several analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. Leerink Partners restated an "outperform" rating and set a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Chardan Capital lifted their price target on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a "buy" rating in a report on Thursday, September 19th. Finally, BMO Capital Markets cut their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an "outperform" rating on the stock in a report on Thursday, July 18th.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded down $0.18 during midday trading on Tuesday, reaching $7.89. 384,588 shares of the company's stock traded hands, compared to its average volume of 887,286. The company has a market cap of $410.04 million, a price-to-earnings ratio of -3.47 and a beta of 2.82. 4D Molecular Therapeutics has a one year low of $7.72 and a one year high of $36.25. The stock has a 50 day moving average of $10.88 and a 200 day moving average of $17.48.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in 4D Molecular Therapeutics during the third quarter worth about $40,000. Values First Advisors Inc. purchased a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. lifted its position in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock worth $108,000 after buying an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $108,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company's stock worth $110,000 after acquiring an additional 3,026 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.